Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.
Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C. Juul N, et al. Among authors: sotiriou c. Lancet Oncol. 2010 Apr;11(4):358-65. doi: 10.1016/S1470-2045(10)70018-8. Epub 2010 Feb 26. Lancet Oncol. 2010. PMID: 20189874 Free article.
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Sotiriou C, et al. J Natl Cancer Inst. 2006 Feb 15;98(4):262-72. doi: 10.1093/jnci/djj052. J Natl Cancer Inst. 2006. PMID: 16478745
Gene expression profiling in breast cancer.
Sotiriou C, Desmedt C. Sotiriou C, et al. Ann Oncol. 2006 Sep;17 Suppl 10:x259-62. doi: 10.1093/annonc/mdl270. Ann Oncol. 2006. PMID: 17018735 Free article. Review. No abstract available.
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Gong Y, et al. Among authors: sotiriou c. Lancet Oncol. 2007 Mar;8(3):203-11. doi: 10.1016/S1470-2045(07)70042-6. Lancet Oncol. 2007. PMID: 17329190
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, Chan S, Perren T, Aapro M, Sotiriou C, Piccart MJ, Larsimont D, Isola J; TAX 303 translational study team. Di Leo A, et al. Among authors: sotiriou c. Ann Oncol. 2007 Jun;18(6):997-1003. doi: 10.1093/annonc/mdm075. Epub 2007 Mar 17. Ann Oncol. 2007. PMID: 17369602 Free article. Clinical Trial.
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C. Loi S, et al. Among authors: sotiriou c. J Clin Oncol. 2007 Apr 1;25(10):1239-46. doi: 10.1200/JCO.2006.07.1522. J Clin Oncol. 2007. PMID: 17401012
401 results